[{"orgOrder":0,"company":"SynDevRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 1b\/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eribulin","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SynDevRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SynDevRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SynDevRx \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by SynDevRx
Details :
First prospective study for Evexomostat (SDX-7320) , aims to demonstrate that restoring insulin sensitivity in breast cancer patients with baseline insulin resistance will improve clinical outcomes.